Skip to contentB
Biofrontera Inc.
B
BFRIBiofrontera Inc. Q3 2023 · 10-Q
Revenue$8.90M$8.90M+105.8% vs Q3 2022 Net Income-$6.34M-$6.34MN/M vs Q3 2022 EPS Diluted-$4.64-$4.64N/M vs Q3 2022 Operating Income-$4,620,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biofrontera Inc. · CIK 1858685 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$2,004,000N/M Margins · derivedOperating margin-51.9%+32.3 pt vs Q3 2022
Net margin-71.3%−11.9 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 9, 2023 · 40 d after period end